Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Cubist Pharmaceuticals
So what: Cubist granted Teva Pharmaceutical Industries
Now what: Teva's sales of the generic version of Cubicin are not slated to begin until December 2017 at the earliest, so investors should not anticipate near-term revenues from the deal. That said, Cubist's CEO noted that the settlement would better allow the company to work with others to develop its business and "eliminated uncertainty." According to analysts, the settlement clears the way for a potential buyout of Cubist by a large drugmaker.
Interested in more info on Cubist Pharmaceuticals? Add it to your watchlist by clicking here.
Fool contributor Cindy Johnson owns shares of Cubist Pharmaceuticals. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.